Abbott Laboratories (NYSE:ABT) Upgraded at Rothschild & Co Redburn

Rothschild & Co Redburn upgraded shares of Abbott Laboratories (NYSE:ABT) from a neutral rating to a buy rating in a research note issued to investors on Friday, Marketbeat reports. They currently have $127.00 price target on the healthcare product maker’s stock, up from their previous price target of $119.00.

Several other equities analysts also recently issued reports on the company. TD Cowen reiterated a “buy” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, September 8th. Bank of America lowered their target price on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. UBS Group reduced their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $119.80.

Abbott Laboratories Trading Up 0.0%

Shares of ABT stock opened at $97.52 on Friday. The company has a market capitalization of $168.75 billion, a P/E ratio of 31.56, a P/E/G ratio of 1.81 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $135.37. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a 50-day moving average price of $106.99 and a 200 day moving average price of $98.60.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the firm earned $1.26 earnings per share. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Institutional Trading of Abbott Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABT. Miller Global Investments LLC lifted its position in Abbott Laboratories by 17.3% during the 3rd quarter. Miller Global Investments LLC now owns 1,890 shares of the healthcare product maker’s stock valued at $187,000 after purchasing an additional 279 shares during the period. Polaris Financial Partners acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $129,000. First Financial Bank Trust Division raised its stake in shares of Abbott Laboratories by 2.2% during the third quarter. First Financial Bank Trust Division now owns 102,483 shares of the healthcare product maker’s stock worth $10,128,000 after buying an additional 2,180 shares during the last quarter. Burkett Financial Services LLC lifted its holdings in Abbott Laboratories by 22.0% in the third quarter. Burkett Financial Services LLC now owns 1,742 shares of the healthcare product maker’s stock valued at $172,000 after buying an additional 314 shares during the period. Finally, Hickory Point Bank & Trust boosted its stake in Abbott Laboratories by 20.7% in the third quarter. Hickory Point Bank & Trust now owns 1,749 shares of the healthcare product maker’s stock valued at $173,000 after acquiring an additional 300 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Rothschild & Co Redburn upgraded Abbott from “neutral” to “buy” and raised its price target to $127 from $119. The new target implies roughly 30% upside from the referenced trading level, providing the clearest catalyst for the stock’s recent strength. Rothschild & Co Redburn upgrades Abbott Laboratories to Buy From Neutral, Adjusts PT
• Positive Sentiment: Abbott is included among low-beta healthcare stocks viewed as relatively defensive amid interest-rate uncertainty and market volatility. Its diversified healthcare portfolio and dividend profile may appeal to investors seeking stability. Low-Beta Healthcare Stocks to Buy
• Positive Sentiment: Industry forecasts point to continued growth in disposable medical sensors and biomarkers, markets that include Abbott and could support longer-term demand for its diagnostics and monitoring products. Disposable Medical Sensors Market Forecasts Growth
• Neutral Sentiment: Analysts expect Abbott’s upcoming third-quarter report to show single-digit earnings growth. The results and management outlook will be important for validating the bullish price-target revision. Abbott Laboratories Quarterly Earnings Preview
• Negative Sentiment: Abbott recently underperformed the broader market, and its price remains below the 50-day moving average, indicating lingering technical pressure despite the analyst upgrade. Abbott Sees a More Significant Dip Than the Broader Market

About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.